e-Newsletter – February 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Search
Search results
Volunteering FAQs
These are some of the most commonly asked questions about volunteering for our charity.
Nobel Prize celebrates breakthrough science behind emerging sight-restoration research
A groundbreaking technology that uses light to control nerve cells has been recognised with the 2026 Nobel Prize.
Meet our Trustee: Dr Elizabeth Graham FRCP FRCOphth
Dr Graham undertook research into the basic mechanisms of retinal vasculitis, inflammation of the blood vessels in the retina, and is an important cause of poor vision in patients with uveitis, inflammation of the uveal tract.
Webinar: Career pathways for young people with sight loss
Join us for our upcoming webinar!
Opus genetics launches clinical trial for MERTK-related retinitis pigmentosa
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Retina UK Clinical and Patient Registry Focus Groups
Retina UK Clinical and Patient Registry Focus Groups
Seeing the light: Scientists use photoswitch drugs to restore vision in animal study
A consortium of researchers based at the Institute for Bioengineering of Catalonia (IBEC) have demonstrated that specially designed light-activated drugs can restore useful visual function in blind animals by making surviving retinal nerve cells respond to light.
Atsena Therapeutics present positive clinical data for LCA1 gene therapy program
Astena Theraputics' investigational gene therapy, ATSN-101, has shown promising long-term results in an early clinical trial for LCA1, a sever inherited retinal disease caused by mutations in the GUCY2D gene.